business models


Moving to an "Outcomes" World with Steve Burrill

Podcast brought to you by: BioConference Live's annual Clinical Diagnostics Conference, May 29-31

Guests:

Steve Burrill, CEO, Burrill and Co Bio and Contact Info

Listen (4:38) Burrill and Buck Conference on Aging

Listen (7:32) Moving to a world in healthcare where we will pay for outcomes

Listen (6:23) Has it not always been about values?

Listen (4:24) Can Pharma create value outside of providing drugs?

Listen (1:08) Thoughts on gene patent case

"This is not your grandfather’s Buick anymore. If you grew up in biotech any time prior to the last five years, you need to reexamine your assumptions about the world of reimbursement." Ron Cohen, CEO, Acorda

This quote is taken from the yearly state of the industry book put out by Burrill and Company. CEO, Steve Burrill joins us today to discuss the newly published book this year subtitled, "Capturing Value." Cohen's quote summarizes the message in the book in which Burrill and his team argue persuasively that things in healthcare are not the way they used to be, that we are moving from a "cost-based" to a "value-based" system. Steve discusses this paradigm shift in today's show and explains why we need new assumptions in the world of pharma and biotech.

Early in the interview, Steve previews the first Burrill and Buck Aging Conference coming up May 20-21 in Novato California. The interview ends with Burrill's thoughts on the Myriad gene patent case.

Improving the Playing Field for Biotech Startups: Melinda Richter, Prescience

Podcast brought to you by: Chempetitive Group - Who for more than a decade has helped science-based companies build and execute innovative marketing campaigns. "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."

Guest:

Melinda Richter, Founder, Prescience Bio and Contact Info

Listen (10:28) How are you accelerating the commercialization of life science technology?

Listen (7:47) Innovation centers helping out startups

Listen (2:55) Educating entrepreneurs

Listen (8:27) Jumping the financial hurdle

Lying in a Beijing hospital bed waiting and waiting for a diagnosis, Melinda Richter, a telecom executive on assignment in Asia, had one of those look-death-in-the-face experiences. "We're here once only, and we have to live our time well," she says in today's interview.

This brush with her mortality propelled Ms. Richter to do something that made a difference to others. This led her to the life science industry, where she found much greater hurdles to entrepreneurship than she had seen in high tech. Asking herself what she could do to help startups and speed up the time for commercializing what is some great technologies led her to found Prescience International. Prescience runs two 'innovation centers', San Jose Biocenter and Janssen Labs in San Diego. In today's show, Melinda describes what these incubator spaces are doing to help lower the barriers for life science startups to get off their feet. Prescience also offers courses for entrepreneurs to get hands on training industry leaders.

Personalized Medicine: A New Industry Struggles Toward Birth

Some argue that medicine has always been personal. Personalized medicine as we think of it today has become the industry that is advancing the understanding of the human body at the molecular level. Since the sequencing of the human genome, this new industry has topped the news, often with much hype but little to show. Last week, Burrill and Co put on their 8th Annual Personalized Medicine Conference in San Francisco.

The Best of Times, the Worst of Times with Bruce Jenett, DLA Piper

Podcast Sponsor: Ingenuity - iReport, the fastest and most accurate way to get biological meaning from your expression data. www.ingenuity.com/get iReport/

Guest:

Bruce Jenett, Partner, DLA PIPER Bio and Contact Info

Chapters: (Advance the marker)

0:49 Taking a macro look at the industry

3:54 The dirty secrets of VC

9:59 The myth that no one funds early stage company

17:31 An attorney in Silicon Valley is expected to help a company get funded

22:50 We're digging a gold mine with a teaspoon

27:58 What do you think of open collaboration?

36:10 Where do you go for your information?

Bruce Jenett is a partner at the global law firm, DLA Piper. Bruce has been in the industry for 30 years representing life science customers. He says the job of an attorney in this industry is to help their clients raise money. Bruce came up with the Dickensian title for today's show. From his perch, Bruce offers a macro picture of the industry and shares some of the dirty little secrets he's picked up along the way.

IBM's Lessons for the Life Sciences with Katherine Holland

Podcast brought to you by: Assay Depot - the world's largest cloud-based marketplace for research services. With Assay Depot, you can easily find the perfect research service provider and manage your project from anywhere in the world.

Guest:

Katherine Holland, Global General Manager, Life Sciences, IBM Bio and Contact Info

Listen (9:50) How is IBM making a difference in the life sciences?

Listen (4:36) IBM's own transformation story

Listen (4:22) Pharma must go from product to service based model

Listen (6:41) Life science companies will interact more and more with "the consumer"

Listen (2:22) Personal path to IBM

Listen (6:33) Leveraging experience in other industries

In the mid-90's IBM came perilously close to running out of cash before transforming from a product based business (remember the unsuccessful OS/2?) to a service based model. It's one of the biggest turn-around stories of our generation. Katherine Holland is IBM's VP for Global Life Sciences, and she thinks there's a lesson or two for pharma and other life science companies in her company's story. Join us as she tells of IBM's transformation and shares her thoughts on future imperatives for the life sciences.

In the Shoes of the Biotech CEO

To raise awareness of and preview the upcoming sessions at the BioExec Institute, Prescience (with UC Berkeley and Deloitte as partners) has been putting on some terrific discussion nights with thought leaders of the biopharma industry. Last night, at one of their typical hip venues in San Francisco, they hosted a panel discussion titled The Corner Office, What Is It Really Like to Be a Biotech CEO? Leading the discussion was Jim Schaeffer from Merck.

Life Science Version of "Cosi Fan Tutte" Plays in Napa, CA

Recently I met Dr. Robert Lee Kilpatrick, co-founder of TVG or Tech Vision Group. Robert is an industry thought leader who’s been around the life sciences for a long time and produces global life science events. Robert sees himself as a biotech gadfly, or one who shakes things up. I might call him an impresario, one who produces high level events with flair and taste. Robert has made sure that I don’t refer to his meetings as conferences. What then should we call them?

Leading Through Creative Investment: Corey Goodman, VenBio

Podcast brought to you by: Assay Depot - the world's largest cloud-based Research Exchange for pharmaceutical research services.

1:53 A new model of investing at VenBio

10:13 All the leaders of big pharma know the industry is in crisis

14:54 Attempt to change Pfizer

24:10 What excites you about the industry?

26:52 Influenced by Buddhism

32:13 City kid on a ranch

Dr. Corey Goodman is a man of many talents with an illustrious background in bio. He’s a renowned scientist, entrepreneur, educator, and corporate executive. And now his latest role is that of investor as a Partner in the VC firm, VenBio. He has been President of Pfizer’s Biotherapeutics and Bioinnovation Center, was co-founder of Exelixis and Renovis, and was a professor at Stanford Univeristy and UC Berkeley for over two decades. He’s currently an adjuct professor at UC San Francisco. Corey talks about the new model of investing he's pursuing with VenBio. He gives insight into his brief stint at Pfizer where he fostered an impressive ambition to change from the inside the world's largest drug maker. Beginning with the goal of creating a Pfizer Genentech, Corey left the pharma giant after just two years without being able to do much change at all. Corey works part of the week from his ranch, where the interview is taped, and shares some of his personal thoughts on the industry and on life. He also shares some of his music.



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup